+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances



Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances



Journal of Drug Targeting 24(3): 192-211



Protein tyrosine kinases are enzymes that catalyze the transfer of phosphate groups from ATP to tyrosine residues on other proteins as substrate. Phosphorylation at tyrosine residues regulates several functions, including enzyme activity, cellular localization, signal transduction and interactions between proteins. Non-receptor tyrosine kinases (nRTKs) are one of the main players in intracellular signaling pathways. Dysregulation of nRTKs leads to their constitutive activation, which might contribute to initiation or progression of cancer. Therefore, targeting dysregulated nRTKs may prevent the process of tumorigenesis. Targeted-based cancer therapy (TBCT) methods and agents or personalized medicine have emerged as the main tools for cancer treatment. Currently, several TBCT agents, including monoclonal antibodies (mAbs) and small molecules inhibitors of tyrosine kinases (TKIs) have been developed. TKIs of cytoplasmic kinases inhibit intracellular signaling pathways and interfere with tumor cell functions. In this article, the recent progresses in development of TKIs of nRTKs approved by the US Food and Drug Administration (FDA) and current promising TKIs in pre-clinical and clinical settings have been reviewed.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058974638

Download citation: RISBibTeXText

PMID: 26211367

DOI: 10.3109/1061186x.2015.1068319


Related references

Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. American Journal of Pharmacogenomics 5(2): 101-112, 2005

An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. European Journal of Medicinal Chemistry 126: 476-490, 2016

Small molecule inhibitors of receptor tyrosine kinases. Drugs of the Future 24(5): 515-537, 1999

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacological Research 2018, 2018

Recent Advances in the Development of Selective Small Molecule Inhibitors for Cyclin-Dependent Kinases. Current Topics in Medicinal Chemistry 5(2): 167-179, 2005

Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. Current Topics in Medicinal Chemistry 5(2): 167-179, 2005

Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. Journal of Drug Targeting 25(3): 189-201, 2016

Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). Current Pharmaceutical Design 9(7): 567-581, 2003

Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Research 73(11): 3402-3411, 2014

Small-molecule Inhibitors of Fibroblast Growth Factor Receptor (Fgfr) Tyrosine Kinases (Tk). Current Pharmaceutical Design 9(7): 567-581, 2003

Promiscuity and selectivity of small-molecule inhibitors across TAM receptor tyrosine kinases in pediatric leukemia. Journal of Molecular Graphics and Modelling 75: 125-131, 2017

Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies. International Journal of Molecular Sciences 15(8): 13768-13801, 2015

Recent Advances in the Development of Small-Molecule Compounds Targeting HIV- 1 gp41 as Membrane Fusion Inhibitors. Mini-Reviews in Organic Chemistry 9(1): 20-26, 2012

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation. Febs Letters 588(5): 653-658, 2014

Effects of epigenetic modificators in combination with small molecule inhibitors of receptor tyrosine kinases on medulloblastoma growth. Biochemical and Biophysical Research Communications 450(4): 1600-1605, 2014